What changed
$TGT — WATCHLIST 📊 | 6 MONTHS THESIS
🧭 Conviction: MED
🎯 FQ1 FY2027 (ends Apr) | reported May 20 | Rev $25.4B | EPS $1.71 vs $1.46 🟢 | Margin 4.5%
💡 Consensus may be too negative following a string of disappointments, with the beat indicating initial stabilization; however, structural headwinds keep risk/reward unattractive at current valuation.
🏢 Business Quality: 4/10
📊 Valuation: Fair — P/E 20.5x, EV/EBITDA 10.7x, in line with historical retail peers but negative FCF makes DCF unreliable; range $120-$160.
🔮 Catalyst: Next quarterly earnings (expected Aug 2026)
⚖️ Watchlist: Target's EPS beat is promising but insufficient to overcome structural headwinds; wait for sustained FCF improvement before committing.